U.S. authorizes more batches of J&J COVID-19 vaccine made at Emergent -Breaking
[ad_1]
© Reuters. FILE PHOTO: Johnson & Johnson’s coronavirus disease (COVID-19) vaccines are seen at Northwell Health’s South Shore University Hospital in Bay Shore, New York, U.S., March 3, 2021. REUTERS/Shannon Stapleton(Reuters) – The U.S. Food and Drug Administration said on Friday it had authorized the use of two more batches of Johnson & Johnson (NYSE:)’s one-dose COVID-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc.
FDA approved 11 batches to the vaccine that were manufactured at this facility.
In April, U.S. authorities halted production after ingredients from AstraZeneca (NASDAQ:)’s COVID-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J’s vaccine.
The authorization granted today was the result of a detailed review by facility records and quality testing done by the manufacturer. This is in light of the COVID-19 public emergency.
An estimated 30 million to 50 million doses of Johnson & Johnson’s COVID-19 vaccine made early this year have been sitting idle in the Baltimore plant for weeks awaiting a green light from U.S. regulators to ship, two sources familiar with the matter told Reuters late last month.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]
